Elicio Therapeutics (ELTX) Current Assets (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Current Assets came in at $16.2 million in Q1 2026, down 22.62% YoY from $20.9 million in Q1 2025, and down 16.11% on a QoQ basis from $19.3 million in Q4 2025.
Elicio Therapeutics (ELTX) Current Assets (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Current Assets data on file, last reported at $16.2 million in Q1 2026.
- Quarterly Current Assets fell 22.62% year-over-year to $16.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.2 million (down 22.62% YoY) and the FY2025 annual result came in at $19.3 million, down 6.68% from the prior year.
- Current Assets fell to $16.2 million in Q1 2026, from $19.3 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $76.2 million in Q1 2022 to a low of $6.7 million in Q2 2024.
- A 5-year average of $28.5 million and a median of $20.9 million in 2025 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets slumped 88.25% — and 2025, when it soared 237.84%.
- Tracing ELTX's Current Assets over 5 years: stood at $10.7 million in 2022, then surged by 52.54% to $16.3 million in 2023, then increased by 26.58% to $20.7 million in 2024, then slipped by 6.68% to $19.3 million in 2025, then slipped by 16.11% to $16.2 million in 2026.
- The last three Current Assets figures came in at $16.2 million (Q1 2026), $19.3 million (Q4 2025), and $21.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 25.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.49 Mn |
| Mar 31, 2026 | 16.20 Mn |
| Dec 31, 2025 | 19.31 Mn |
| Sep 30, 2025 | 21.47 Mn |
| Jun 30, 2025 | 22.60 Mn |
| Mar 31, 2025 | 20.94 Mn |
| Dec 31, 2024 | 20.69 Mn |
| Sep 30, 2024 | 30.65 Mn |
| Jun 30, 2024 | 6.69 Mn |
| Mar 31, 2024 | 14.13 Mn |
| Dec 31, 2023 | 16.35 Mn |
| Sep 30, 2023 | 19.93 Mn |
| Jun 30, 2023 | 26.23 Mn |
| Mar 31, 2023 | 40.63 Mn |
| Dec 31, 2022 | 10.72 Mn |
| Sep 30, 2022 | 56.68 Mn |
| Jun 30, 2022 | 65.89 Mn |
| Mar 31, 2022 | 76.24 Mn |
| Dec 31, 2021 | 91.25 Mn |
| Sep 30, 2021 | 104.39 Mn |